Humacyte, Inc. — Director's Dealing 2022

Dec 20, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-12-15

Reporting Person: Niklason Laura E (Director, President, CEO and Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-15	Common Stock	P	10000	$2.54	Acquired	1170240	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	17990736	Indirect
Common Stock	510161	Indirect

Footnotes

F1: This purchase is matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, against a portion of the sale by Ayabudge LLC, an entity controlled by the Reporting Person's spouse, of 1,522,500 shares of the Issuer's common stock on September 15, 2022, at a per share price of $4.00. The Reporting Person has paid the Issuer $14,604.95, representing the full amount of profit realized in connection with this purchase.

F2: The price is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $2.53 to $2.55. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.